Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
Latest News
Unexpected hydroxylation
20 May 2022
Vacancy - Senior Postdoctoral Researcher
17 May 2022
Vacancy: Research Integrity Manager
6 May 2022
Recent publications
-
Factor inhibiting HIF can catalyse two asparaginyl-hydroxylations in VNVN motifs of ankyrin fold proteins.
Journal article
Leissing TM. et al, (2022), The Journal of biological chemistry
-
T-cell mediated targeted delivery of anti-PD-L1 nanobody overcomes poor antibody penetration and improves PD-L1 blocking at the tumor site
Journal article
Petit P-F. et al, (2022), Cancer Immunology Research
-
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming.
Journal article
Chu Z. et al, (2022), Nature communications, 13
Seminars
FOLLOW US
Outreach
Study with us
Work with us
HEALTH INFORMATION
Please refer to the University of Oxford Health page for updated health guidance.